Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion
SOUTH SAN FRANCISCO, Calif., May 5, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) (the "Company" or "Portola") today announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the first quarter ended March 31, 2020 that was previously scheduled for Monday, May 11, 2020, at 4:30 p.m. ET (1:30 p.m. PT).
This cancellation is due to the announcement on May 5, 2020, that Portola has entered into a definitive merger agreement to be acquired by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). Portola will issue a press release reporting its first quarter 2020 financial results on Monday, May 11, 2020. The press release will be available on the Company's website at www.portola.com.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The Company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
SOURCE Portola Pharmaceuticals, Inc.®
For further information: Investor Contact, Jennifer Zibuda, Portola Pharmaceuticals, IR@portola.com; Media Contact, Emily Faucette, Portola Pharmaceuticals, Media@portola.com